No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy
- 1 April 1988
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 114 (2) , 183-185
- https://doi.org/10.1007/bf00417834
Abstract
The results of clinical studies dealing with first and second line chemotherapy of metastatic breast cancer published between 1975 and early 1986 which involved 9350 women were reviewed. Our special aim was to evaluate combination chemotherapy and its influence on overall survival in late stage breast cancer patients. No significant improvement in overall survival times was found in this selected group of patients who were treated with intense palliative chemotherapy.Keywords
This publication has 8 references indexed in Scilit:
- Alkyl phosphocholines: Toxicity and anticancer propertiesLipids, 1987
- Antimetastatic effects of razoxane in a rat osteosarcoma modelClinical & Experimental Metastasis, 1987
- Bedeutung der Zusammensetzung verschiedener Kombinationsschemata bei der Chemotherapie des metastasierten MammakarzinomsDeutsche Medizinische Wochenschrift (1946), 1987
- ON THE RELEVANCE OF 2ND-LINE CYTOTOXIC CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER RESISTANT TO STANDARD COMBINATIONS1986
- Estrogen-linked 2-chloroethylnitrosoureas: Anticancer efficacy in MNU-induced rat mammary carcinoma, uterine activity in mice and receptor interactionsEuropean Journal of Cancer and Clinical Oncology, 1986
- Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?Cancer, 1986
- SYNTHESIS, TOXICITY, AND THERAPEUTIC EFFICACY OF 4-AMINO-N-(2'-AMINOPHENYL)-BENZAMIDE - A NEW COMPOUND PREFERENTIALLY ACTIVE IN SLOWLY GROWING TUMORS1985